REGENXBIO, Inc. (RGNX)
7.11
-0.30
(-4.05%)
USD |
NASDAQ |
Oct 30, 12:04
REGENXBIO Enterprise Value : 546.08M for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | 546.08M |
| October 28, 2026 | 536.87M |
| October 27, 2026 | 502.20M |
| October 26, 2026 | 501.12M |
| October 23, 2026 | 506.54M |
| October 22, 2026 | 533.08M |
| October 21, 2026 | 533.08M |
| October 20, 2026 | 545.53M |
| October 19, 2026 | 531.99M |
| October 16, 2026 | 519.81M |
| October 15, 2026 | 532.53M |
| October 14, 2026 | 517.37M |
| October 13, 2026 | 537.95M |
| October 12, 2026 | 565.57M |
| October 09, 2026 | 581.82M |
| October 08, 2026 | 582.91M |
| October 07, 2026 | 556.10M |
| October 06, 2026 | 548.24M |
| October 05, 2026 | 565.03M |
| October 02, 2026 | 547.16M |
| October 01, 2026 | 546.62M |
| September 30, 2026 | 552.57M |
| September 29, 2026 | 548.24M |
| September 28, 2026 | 549.33M |
| September 25, 2026 | 545.53M |
| Date | Value |
|---|---|
| September 24, 2026 | 536.87M |
| September 23, 2026 | 550.95M |
| September 22, 2026 | 586.16M |
| September 21, 2026 | 571.53M |
| September 18, 2026 | 579.66M |
| September 17, 2026 | 589.68M |
| September 16, 2026 | 576.95M |
| September 15, 2026 | 575.05M |
| September 14, 2026 | 615.41M |
| September 11, 2026 | 606.74M |
| September 10, 2026 | 608.36M |
| September 09, 2026 | 617.57M |
| September 08, 2026 | 619.20M |
| September 04, 2026 | 628.95M |
| September 03, 2026 | 643.03M |
| September 02, 2026 | 664.69M |
| September 01, 2026 | 649.53M |
| August 31, 2026 | 659.28M |
| August 28, 2026 | 667.94M |
| August 27, 2026 | 652.24M |
| August 26, 2026 | 652.78M |
| August 25, 2026 | 627.32M |
| August 24, 2026 | 581.01M |
| August 21, 2026 | 725.36M |
| August 20, 2026 | 743.77M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AbbVie, Inc. | 578.15B |
| United Therapeutics Corp. | 22.67B |
| Biomea Fusion, Inc. | 10.83M |
| RenovoRx, Inc. | 58.14M |
| ACADIA Pharmaceuticals, Inc. | 2.691B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 22.71M |
| Revenue (Quarterly) | 108.02M |
| Total Expenses (Quarterly) | 85.31M |
| EPS Diluted (Quarterly) | 0.4283 |
| Gross Profit Margin (Quarterly) | 95.56% |
| Profit Margin (Quarterly) | 21.02% |
| Earnings Yield | -53.24% |
| Normalized Earnings Yield | -53.24 |